tbuckley/cabot-search huggingface dataset:
Contract and ownership type of general practices and patient experience in England: multilevel analysis of a national cross-sectional survey
Authors: Thomas E Cowling, Anthony A Laverty, Matthew J Harris, Hilary C Watt, Felix Greaves, Azeem Majeed
Journal: Journal of the Royal Society of Medicine (2017)

Objective To examine associations between the contract and ownership type of general practices and patient experience in England. Design Multilevel linear regression analysis of a national cross-sectional patient survey (General Practice Patient Survey). Setting All general practices in England in 2013-2014 ( n = 8017). Participants 903,357 survey respondents aged 18 years or over and registered with a general practice for six months or more (34.3% of 2,631,209 questionnaires sent). Main outcome measures Patient reports of experience across five measures: frequency of consulting a preferred doctor; ability to get a convenient appointment; rating of doctor communication skills; ease of contacting the practice by telephone; and overall experience (measured on four- or five-level interval scales from 0 to 100). Models adjusted for demographic and socioeconomic characteristics of respondents and general practice populations and a random intercept for each general practice. Results Most practices had a centrally negotiated contract with the UK government ('General Medical Services' 54.6%; 4337/7949). Few practices were limited companies with locally negotiated 'Alternative Provider Medical Services' contracts (1.2%; 98/7949); these practices provided worse overall experiences than General Medical Services practices (adjusted mean difference -3.04, 95% CI -4.15 to -1.94). Associations were consistent in direction across outcomes and largest in magnitude for frequency of consulting a preferred doctor (-12.78, 95% CI -15.17 to -10.39). Results were similar for practices owned by large organisations (defined as having ≥20 practices) which were uncommon (2.2%; 176/7949). Conclusions Patients registered to general practices owned by limited companies, including large organisations, reported worse experiences of their care than other patients in 2013-2014.
Patients’ view of routine follow-up after breast cancer treatment.
Authors: E. Greimel, M. Lambauer, M. Dorfer, G. Pristauz, G. Luschin-Ebengreuth, A. Bader, E. Petru, C. Benedicic, A. Lanz-Veit, S. Gramm, J. Czihak, D. Ulrich, K. Tamussino, V. Bjelic-Radisic
Journal: Journal of Clinical Oncology (2011)

e19516 Background: Routine follow-up of women treated for breast cancer comprises the evaluation of care, early detection of recurrences, and reassurance of patients. The objective was to assess patients’ level of emotional distress and anxiety before routine follow-up visits, physical well being, satisfaction with life, and emotional stress reactions, as well their view of the routine follow up. Methods: Women with the history of breast cancer diagnosed at least of 3 months ago were asked to complete the Breast Cancer Psychosocial Assessment Screening scale (BC-PASS) and a questionnaire about their views of follow up. Results: Between September and December 2009 we included 284 patients were included in the study. 51% of patients were within the first two years of follow up, 31% between the second and fifth year and 16% were in follow-up for more than five years. 10% of patients had metastatic breast cancer with a low degree of symptoms. On the BC-PASS scale, the majority of patients showed low levels of distress. The mean score on the physical well-being scale was 4.00 (SD 3.1), on the satisfaction with life scale 6.00 (SD 4.1), and on the emotional distress scale 7.00 (SD 4.2), respectively. Women rated mammography as the most important component of the follow up visit (68%), followed by breast ultrasound (60%) and the doctors’ interview (57%). The doctors’ interview was rated the least distressing component (72%) followed by breast palpation (58%) and breast ultrasound (49%). 23% of patients reported tension, 33% disturbance and 24% showed anxiety before the routine follow up. Conclusions: Women undergoing routine follow-up visits after breast cancer are satisfied with the current follow-up care. The psychological support patients perceive due to regular visits is highly valued. Patient-reported outcomes should be taken into account when considering changes in the provision of follow-up care in breast cancer.
Beyond the triad: Inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita
Authors: Suzanne C. Ward, Sharon A. Savage, Neelam Giri, Blanche P. Alter, Philip S. Rosenberg, Dominique C. Pichard, Edward W. Cowen
Journal: Journal of the American Academy of Dermatology (2017)
Patient Perceptions About Their Physician in 2 Words
Authors: Brandon Singletary, Nisha Patel, Martin Heslin
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Authors: Axel Grothey, Jonathan R. Strosberg, Lindsay A. Renfro, Herbert I. Hurwitz, John L. Marshall, Howard Safran, Michael J. Guarino, George P. Kim, J.R. Hecht, Susan C. Weil, John Heyburn, Wenquan Wang, Charles Schweizer, Daniel J. O'Shannessy, Luis Alberto Diaz
Journal: Clinical Cancer Research (2017)

Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers.Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab.Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76-1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab.Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316-25. ©2017 AACR.
PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer
Authors: K.M. Sheffield, Y.E. Zhu, Y. Fang, K.B. Winfree, G. Cuyun Carter, Y. Huang
Journal: Journal of Thoracic Oncology (2017)
Developing Cancer Informatics Applications and Tools Using the NCI Genomic Data Commons API
Authors: Shane Wilson, Michael Fitzsimons, Martin Ferguson, Allison Heath, Mark Jensen, Josh Miller, Mark W. Murphy, James Porter, Himanso Sahni, Louis Staudt, Yajing Tang, Zhining Wang, Christine Yu, Junjun Zhang, Vincent Ferretti, Robert L. Grossman
Journal: Cancer Research (2017)

The NCI Genomic Data Commons (GDC) was launched in 2016 and makes available over 4 petabytes (PB) of cancer genomic and associated clinical data to the research community. This dataset continues to grow and currently includes over 14,500 patients. The GDC is an example of a biomedical data commons, which collocates biomedical data with storage and computing infrastructure and commonly used web services, software applications, and tools to create a secure, interoperable, and extensible resource for researchers. The GDC is (i) a data repository for downloading data that have been submitted to it, and also a system that (ii) applies a common set of bioinformatics pipelines to submitted data; (iii) reanalyzes existing data when new pipelines are developed; and (iv) allows users to build their own applications and systems that interoperate with the GDC using the GDC Application Programming Interface (API). We describe the GDC API and how it has been used both by the GDC itself and by third parties.
Hypoxia impairs morphological and functional differentiation of immortalized human breast epithelial cells in 3D Matrigel-culture.
Authors: Annika Jogi, Karolina Helczynska, Elisabet Johansson, Siv Beckman, Christer Larsson, Sven Pahlman
Journal: Cancer Research (2008)

2060   Solid tumors are generally less well oxygenated than normal tissue. Hypoxia infers several properties on the tumor cells, such as adapted metabolism, resistance to radiotherapy and some chemotherapeutic agents. Pronounced tumor hypoxia has also been associated with increased metastasis and worse patient outcome. Several hypoxia-induced phenotypic changes have been demonstrated to be driven by the transcriptional regulation of the hypoxia inducible factors 1 and 2. We have previously demonstrated that hypoxia induces a less differentiated phenotype in mammary ductal carcinoma tumors and in cell lines derived from these tumors, and from neuroblastoma. Clinically, a low level of differentiation is linked to aggressive disease and poor prognosis. Cell lines grown at hypoxia express several genes coding for growth and survival factors. Here, we have studied the effect of low oxygen pressure on the ability of immortalized human breast epithelial cells to form acini-like structures in Matrigel-culture. The immortalized cell line MCF-10A, was grown on Matrigel in growth medium supplemented with 2% Matrigel under normoxic and hypoxic conditions for up to three weeks. Even after several weeks of culture at 1% oxygen the MCF-10A cells were thriving and displayed a normal cellular appearance. At normoxia, the MCF-10A cells formed acini with a spherical architecture resembling in vivo acini, with a polarized palisade cell layer surrounding a hollow lumen. In contrast, when cultured under hypoxic conditions, these cells formed dense filled cell lumps generally lacking the outer layer of polarized cells. To further characterize the difference between the normoxic and hypoxic cell structures, we studied the localization of several marker proteins. Human milk fat globule-1, HMFG-1, was deposited basally in the normoxic acini, but exhibited cytoplasmic distribution throughout the entire sphere at hypoxia. Cytoplasmic distribution of HMFG-1 in breast cancer has been associated with aggressive tumor disease and low level of differentiation. Antibodies against the markers of basolateral polarity, alfa-6 integrin and laminin V, stained the basal membrane of normoxic acini, but both displayed a diffuse pattern of distribution throughout the hypoxic spheres. The hypoxic structures were smaller than the normoxic, in agreement with fewer hypoxic cells staining positive for the proliferation marker Ki-67. Currently, we are working on further characterization of the hypoxic cell spheres and studying whether the lack of a hollow lumen in the hypoxic spheres can be related to disturbed apoptosis. In conclusion, we find that hypoxia hampers the morphological and functional differentiation of breast epithelial cells, MCF-10A, grown on Matrigel. We find that this model may provide information on the mechanisms behind the lower level of cell differentiation seen in hypoxic tumors in vivo.
TCT-21 Prevalence, Presentation and Treatment of ‘Balloon Undilatable’ Chronic Total Occlusions: Multicenter US Experience
Authors: Peter Tajti, Dimitri Karmpaliotis, Khaldoon Alaswad, Farouc Amin Jaffer, Robert Yeh, Mitul Patel, Ehtisham Mahmud, James Choi, Nicholas Burke, Anthony Doing, Catalin Toma, Barry Uretsky, Elizabeth Holper, R. Michael Wyman, William Lombardi, David Kandzari, Nicholas Lembo, Santiago Garcia, Oleg Krestyaninov, Dmitrii Khelimskii, Michail Koutouzis, Ioannis Tsiafoutis, Jeffrey Moses, Ajay Jayant Kirtane, Manish Parikh, Raja Hatem, Ziad Ali, Aris Karatasakis, Judit Karacsonyi, Barbara Anna Danek, Bavana Rangan, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2017)
Abstract 339: Combining Urgent Coronary Angiography With Therapeutic Hypothermia Does Not Slow Cooling Times for Comatose Survivors of Cardiac Arrest
Authors: Samuel W Terman, Benjamin D Hume, Daniel S Menees, Robert Silbergleit
Journal: Circulation (2013)

Introduction: Selected comatose survivors of out-of-hospital-cardiac arrest (OHCA) meet criteria for both emergent percutaneous coronary intervention (PCI) and induction of mild therapeutic hypothermia (MTH). It is unclear which should be performed first. We hypothesized that urgent catheterization prior to MTH may significantly prolong time to cooling. Methods: We conducted a retrospective cohort study, reviewing electronic medical records of all patients treated with MTH in the University of Michigan Emergency Department (ED) for OHCA. We identified whether the endovascular cooling device was inserted in the ED or catheterization lab and assessed time from ED arrival to cooling device insertion, to cooling initiation, and to reaching ≤33.5°C. Neurological outcomes were determined by Cerebral Performance Category (CPC) via chart review. Times were compared via Student’s t-tests. Results: Between 7/1/2006 and 9/14/2012, 123 consecutive patients were treated with MTH. Twenty-six (22%) had their device placed in the catheterization lab (14/26 received PCI) while 92 (77%) had theirs placed in the ED. There was no significant difference between catheterization lab v. ED device placement in time from ED arrival to device insertion, arrival to cooling initiation, and arrival to reaching target temperature (see table). Forty-six percent vs 39% of those whose devices were inserted in the catheterization lab vs ED survived past hospital discharge (OR 1.8; 95% CI 0.7-4.4), and 35% vs 39% had favorable 6-month neurological outcomes (OR 1.3; 95% CI 0.5-3.3). Conclusions: In our system, initiating cooling in the catheterization lab as opposed to the ED does not significantly delay cooling times. The resources and efficiencies involved in activation of the cath lab team may offset the time taken to perform angiography and potential subsequent PCI. These data support the practice of immediate cardiac catheterization in appropriate comatose survivors of cardiac arrest.
MA 02.01 Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors
Authors: T. Leal, T. Campbell, A. Mapes, K. Schneider, M.J. Staab, K. Velastegui, J. Christensen, I. Chen, A. Traynor
Journal: Journal of Thoracic Oncology (2017)
Biomolecule‐Responsive Hydrogels in Medicine
Authors: Ghorbanali Sharifzadeh, Hossein Hosseinkhani
Journal: Advanced Healthcare Materials (2017)

Abstract Recent advances and applications of biomolecule‐responsive hydrogels, namely, glucose‐responsive hydrogels, protein‐responsive hydrogels, and nucleic‐acid‐responsive hydrogels are highlighted. However, achieving the ultimate purpose of using biomolecule‐responsive hydrogels in preclinical and clinical areas is still at the very early stage and calls for more novel designing concepts and advance ideas. On the way toward the real/clinical application of biomolecule‐responsive hydrogels, plenty of factors should be extensively studied and examined under both in vitro and in vivo conditions. For example, biocompatibility, biointegration, and toxicity of biomolecule‐responsive hydrogels should be carefully evaluated. From the living body's point of view, biocompatibility is seriously depended on the interactions at the tissue/polymer interface. These interactions are influenced by physical nature, chemical structure, surface properties, and degradation of the materials. In addition, the developments of advanced hydrogels with tunable biological and mechanical properties which cause no/low side effects are of great importance.
Mechanisms and Targeted Therapies for<i>Pseudomonas aeruginosa</i>Lung Infection
Authors: Colleen S. Curran, Thomas Bolig, Parizad Torabi-Parizi
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Pseudomonas aeruginosa is a complex gram-negative facultative anaerobe replete with a variety of arsenals to activate, modify, and destroy host defense mechanisms. The microbe is a common cause of nosocomial infections and an antibiotic-resistant priority pathogen. In the lung, P. aeruginosa disrupts upper and lower airway homeostasis by damaging the epithelium and evading innate and adaptive immune responses. The biology of these interactions is essential to understand P. aeruginosa pathogenesis. P. aeruginosa interacts directly with host cells via flagella, pili, lipoproteins, lipopolysaccharides, and the type III secretion system localized in the outer membrane. P. aeruginosa quorum-sensing molecules regulate the release of soluble factors that enhance the spread of infection. These characteristics of P. aeruginosa differentially affect lung epithelial, innate, and adaptive immune cells involved in the production of mediators and the recruitment of additional immune cell subsets. Pathogen interactions with individual host cells and in the context of host acute lung infection are discussed to reveal pathways that may be targeted therapeutically.
Abstract 19968: Nicotinic Acetylcholine Receptor Signaling is Associated With RV Dysfunction in PAH
Authors: Alexander Vang, Richard Clements, Ayed Allawzi, Richard Kue, Gaurav Choudhary
Journal: Circulation (2016)

Introduction: Limited therapeutic options are available for RV failure associated with Pulmonary Arterial Hypertension (PAH). In this study, we investigated the role of cholinergic pathway and nACh...
Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults
Authors: Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish
Journal: JAMA Neurology (2017)

The goal of Alzheimer disease (AD) prevention together with advances in understanding the pathophysiology of AD have led to clinical trials testing drugs in cognitively unimpaired persons who show evidence of AD biomarkers. Data are needed to inform the processes of describing AD biomarkers to cognitively normal adults and assessing their understanding of this knowledge.To determine the comprehension of an elevated amyloid positron emission tomographic (PET) biomarker result by cognitively unimpaired adults.The Study of Knowledge and Reactions to Amyloid Testing, a substudy of an AD prevention trial, involved 2 semistructured telephone interviews with 80 participants recruited from 9 study sites: 50 received elevated and 30 received not elevated amyloid PET scan results. Interviews were conducted 4 to 12 weeks after result disclosure and again 1 year later. Data presented here were collected from November 5, 2014, through December 10, 2015. The 50 participants included in this study were cognitively normal, aged 65 to 85 years, evenly distributed by gender, and had elevated amyloid PET results. Subsequent reports will examine persons with "not elevated" results and compare the influence of the different results.Participant comprehension of an elevated amyloid result was assessed by analyzing their responses to the following questions: "What was the result of your amyloid PET scan?" (followed by "Can you tell me in your own words what that means?" or "How would you explain it to a friend?"), "Was it the result you expected?" and "Did the result teach you anything or clarify anything for you?"Of the 50 participants aged 65 to 85 years, 49 (98%) were white, 40 (80%) reported a family history of AD, and 30 (60%) had a postgraduate educational level. Most participants (31 [62%]) understood that elevated amyloid conferred an increased but uncertain risk of developing AD. Some desired understanding of the term elevated other than its being a categorical result enabling trial entry eligibility; they wanted information regarding how elevated their amyloid was, how close to the study threshold they were, or percentages, numbers, or a scale to help them make sense of the result.Including an explanation of how and why a dimensional biomarker is converted to a categorical classification would enhance future AD biomarker clinical trials and educational materials.
TCT-739 Comparison of mid-term clinical outcomes after treatment of ostial right coronary artery lesions with early and new generation drug-eluting stents: insights from an international multicenter registry
Authors: Satoru Mitomo, Richard Jabbour, Antonio Mangieri, Marco Ancona, Damiano Regazzoli, Akihiro Nakajima, Toru Naganuma, Francesco Giannini, Azeem Latib, Sunao Nakamura, Antonio Colombo
Journal: Journal of the American College of Cardiology (2017)
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
Authors: R.J. Lee, G. Gremel, A. Marshall, K.A. Myers, N. Fisher, J.A. Dunn, N. Dhomen, P.G. Corrie, M.R. Middleton, P. Lorigan, R. Marais
Journal: Annals of Oncology (2017)

Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.
Field evaluation of an infectious disease/fever screening radar system during the 2017 dengue fever outbreak in Hanoi, Vietnam: a preliminary report
Authors: Guanghao Sun, Nguyen Vu Trung, Takemi Matsui, Koichiro Ishibashi, Tetsuo Kirimoto, Hiroki Furukawa, Le Thi Hoi, Nguyen Nguyen Huyen, Quynh Nguyen, Shigeto Abe, Yukiya Hakozaki, Nguyen Van Kinh
Journal: Journal of Infection (2017)